Eisenberg S. Refractory response to platelet transfusion therapy. J Infus Nurs. 2010;33:89–97.
Google Scholar
Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol. 2008;142:348–60.
Google Scholar
Stanworth SJ, Navarrete C, Estcourt L, Marsh J. Platelet refractoriness–practical approaches and ongoing dilemmas in patient management. Br J Haematol. 2015;171:297–305.
Google Scholar
Kerkhoffs JL, Eikenboom JC, van de Watering LM, van Wordrager-Vlaswinkel RJ, Wijermans PW, Brand A. The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion. 2008;48:1959–65.
Google Scholar
Toor AA, Choo SY, Little JA. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation. Bone Marrow Transpl. 2000;26:315–20.
Google Scholar
Comont T, Tavitian S, Bardiaux L, Fort M, Debiol B, Morère D, et al. Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapy. Leuk Res. 2017;61:62–7.
Google Scholar
Meehan KR, Matias CO, Rathore SS, Sandler SG, Kallich J, LaBrecque J, et al. Platelet transfusions: utilization and associated costs in a tertiary care hospital. Am J Hematol. 2000;64:251–6.
Google Scholar
Bishop JF, McGrath K, Wolf MM, Matthews JP, De Luise T, Holdsworth R, et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood. 1988;71:383–7.
Google Scholar
Murphy MF, Waters AH. Platelet transfusions: the problem of refractoriness. Blood Rev. 1990;4:16–24.
Google Scholar
Doughty HA, Murphy MF, Metcalfe P, Rohatiner AZ, Lister TA, Waters AH. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang. 1994;66:200–5.
Google Scholar
Gouttefangeas C, Diehl M, Keilholz W, Hörnlein RF, Stevanović S, Rammensee HG, et al. molecules retain nonrenewable endogenous peptides of megakaryocyte lineage and do not stimulate direct allocytotoxicity in vitro. Blood. 2000;95:3168–75.
Google Scholar
Forest SK, Hod EA. Management of the Platelet Refractory Patient. Hematol Oncol Clin North Am. 2016;30:665–77.
Google Scholar
Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969;280:735–9.
Google Scholar
Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320:197–204.
Google Scholar
Mattsson J, Ringdén O, Storb R. Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2008;14:165–70.
Google Scholar
Süsal C, Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation. 2002;73:1269–73.
Google Scholar
Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ, et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009;88:1019–24.
Google Scholar
Youk HJ, Hwang SH, Oh HB, Ko DH. Evaluation and management of platelet transfusion refractoriness. Blood Res. 2022;57:6–10.
Google Scholar
Rioux-Massé B, Cohn C, Lindgren B, Pulkrabek S, McCullough J. Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion. Transfusion. 2014;54:3080–7.
Google Scholar
Pons-Estel GJ, Salerni GE, Serrano RM, Gomez-Puerta JA, Plasin MA, Aldasoro E, et al. Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature. Autoimmun Rev. 2011;10:679–84.
Google Scholar
Weinstein R. Basic principles of therapeutic blood exchange. In: McLeod BC, Weinstein R, Winters JL, Szczepiorkowski ZM, editors. Apheresis: principles and practice. 3rd ed. Bethesda: AABB Press; 2010. pp. 269–94.
Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019;34:171–354.
Xu L, Chen H, Chen J, Han M, Huang H, Lai Y, et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol. 2018;11:33.
Google Scholar
Rebulla P, Morelati F, Revelli N, Villa MA, Paccapelo C, Nocco A, et al. Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on cross-matching locally available platelet products. Br J Haematol. 2004;125:83–9.
Google Scholar
Sareban N, Macher S, Drexler C, Posch U, Lanzer G, Schallmoser K. Platelet antibody analysis by three different tests. J Clin Lab Anal. 2015;29:198–202.
Google Scholar
Takanashi M, Atsuta Y, Fujiwara K, Kodo H, Kai S, Sato H, et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood. 2010;116:2839–46.
Google Scholar
Pavenski K, Rebulla P, Duquesnoy R, Saw CL, Slichter SJ, Tanael S, et al. International Collaboration for Guideline Development, Implementation and Evaluation for Transfusion Therapies (ICTMG) Collaborators. Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion. 2013;53:2230–42.
Google Scholar
Kongtim P, Cao K, Ciurea SO. Donor specific anti-HLA antibody and risk of graft failure in haploidentical stem cell transplantation. Adv Hematol. 2016;2016:4025073.
Google Scholar
Bearden CM, Agarwal A, Book BK, Vieira CA, Sidner RA, Ochs HD, et al. Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transplant. 2005;5:50–7.
Google Scholar
Vo P, Purev E, West KA, McDuffee E, Worthy T, Cook L, et al. A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients. Br J Haematol. 2020;189:551–8.
Google Scholar
Chang YJ, Xu LP, Wang Y, Zhang XH, Chen H, Chen YH, et al. Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody. Bone Marrow Transpl. 2020;55:1326–36.
Google Scholar
Bailén R, Vicario JL, Solán L, Sánchez-Vadillo I, Herrera P, Calbacho M, et al. Management of donor-specific antibodies in haploidentical transplant: multicenter experience from the Madrid group of hematopoietic transplant. Front Immunol. 2021;12:674658.
Google Scholar
Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue. J Clin Apher. 2016;31:149–62.
Google Scholar
Ciurea SO, Cao K, Fernandez-Vina M, Kongtim P, Malki MA, Fuchs E, et al. The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transpl. 2018;53:521–34.
Google Scholar
kaposztas z, podder h, mauyyedi s, illoh o, kerman r, reyes m, et al. Impact of ritutimab therapy for treatment of acute humoral rejection. Clin Transplant. 2009;23:63–7
Google Scholar
Cid J, Magnano L, Acosta M, Alba C, Esteve J. Lozano M. Rituximab, plasma exchange and intravenous immunoglobulins as a new treatment strategy for severe HLA alloimmune platelet refractoriness. Platelets. 2015;26:190–4.
Google Scholar
Zheng X, Yan H, Han D, Ding L, Zhu L, Liu J, et al. Successful desensitization of high level donor-specific anti-HLA antibody in patients with hematological diseases receiving haploidentical allografts. Ann Hematol. 2022;101:1777–83.
Google Scholar
Fernández-Zarzoso M, Gómez-Seguí I, de la Rubia J. Therapeutic plasma exchange: review of current indications. Transfusion Apher Sci. 2019;58:247–53.
Google Scholar
Epperla N, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, et al. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. J Hematol Oncol. 2017;10:117.
Google Scholar
Dierickx D, Habermann TM. Post-transplant lymphoproliferative disorders in adults. N Engl J Med 2018;378:549–62.
Google Scholar
